Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avalo TherapeuticsAVTX +7.74%24 3-Year EBITDA Growth Rate is 82.20% as of Jun. 2026, which is 98% above its 10-year median of 41.50. GuruFocus rates AVTX with a GF Score™ of 24/100 and a GF Value™ of $0.05 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,131 Biotechnology companies, Avalo Therapeutics ranks better than 96.82% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 82.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 76.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Avalo Therapeutics was 86.60% per year. The lowest was -37.40% per year. And the median was 41.50% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Avalo Therapeutics 3-Year EBITDA Growth Rate Related Terms
AVTX vs MRVI, LBRX, JANX: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Avalo Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avalo Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avalo Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Avalo Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 82.20% mean?
Avalo Therapeutics (AVTX) has a 3-Year EBITDA Growth Rate of 82.20% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Avalo Therapeutics and its competitors. This is 98% above median its historical median of 41.50. According to the industry distribution chart, Avalo Therapeutics ranks #36 out of 1131 companies in the Biotechnology industry, placing it in the top 3.2%.
Is Avalo Therapeutics' 3-Year EBITDA Growth Rate too high?
Avalo Therapeutics' current 3-Year EBITDA Growth Rate of 82.20% is 98% above median its 10-year median of 41.50. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Avalo Therapeutics' value of 82.20% is 451.7% above this industry median. Based on the distribution chart, Avalo Therapeutics ranks #36 out of 1131 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Avalo Therapeutics has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avalo Therapeutics' 3-Year EBITDA Growth Rate compare to MRVI and LBRX?
According to the Biotechnology industry distribution chart, Avalo Therapeutics ranks #36 out of 1131 companies for 3-Year EBITDA Growth Rate. This places Avalo Therapeutics in the top 3% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.90. Avalo Therapeutics' value of 82.20% is 451.7% above this benchmark. While the company's 10-year median is 41.50 vs. the industry median of 14.90, Avalo Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,131 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avalo Therapeutics's current 3-Year EBITDA Growth Rate of 82.20% is 451.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Avalo Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avalo Therapeutics's current 3-Year EBITDA Growth Rate is 82.20%, which is 98% above median its own 10-year median of 41.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avalo Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Avalo Therapeutics (AVTX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $19.77 — trading 39440% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 82.20%, which is 98% above median its 10-year median of 41.50 and 451.7% above the Biotechnology industry median of 14.90. Avalo Therapeutics' overall GF Score™ is 24/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Avalo Therapeutics (AVTX), the current 3-Year EBITDA Growth Rate is 82.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Avalo Therapeutics (AVTX) Overvalued in 2026?
Based on GuruFocus' analysis, Avalo Therapeutics stock appears to be overvalued.
The current stock price of $19.77 is trading 39440% above its estimated GF Value™ of $0.05.
GuruFocus considers Avalo Therapeutics to be Significantly Overvalued.
Key valuation signals for AVTX:
3-Year EBITDA Growth Rate: 82.20% (98% above median its 10-year median of 41.50)
GF Value™: $0.05 vs. price of $19.77 (39440% above fair value)
Industry Position: 451.7% above the Biotechnology median (#36 of 1131)
No single metric tells the full story. See the AVTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
24GF Score
Get the complete analysis for AVTX
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVTX has been successfully added to your 
